BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23701319)

  • 1. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.
    Eastwood D; Bird C; Dilger P; Hockley J; Findlay L; Poole S; Thorpe SJ; Wadhwa M; Thorpe R; Stebbings R
    Br J Clin Pharmacol; 2013 Aug; 76(2):299-315. PubMed ID: 23701319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. After TGN1412: recent developments in cytokine release assays.
    Stebbings R; Eastwood D; Poole S; Thorpe R
    J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
    Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
    J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
    Eastwood D; Findlay L; Poole S; Bird C; Wadhwa M; Moore M; Burns C; Thorpe R; Stebbings R
    Br J Pharmacol; 2010 Oct; 161(3):512-26. PubMed ID: 20880392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.
    Römer PS; Berr S; Avota E; Na SY; Battaglia M; ten Berge I; Einsele H; Hünig T
    Blood; 2011 Dec; 118(26):6772-82. PubMed ID: 21931118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model.
    Weißmüller S; Kronhart S; Kreuz D; Schnierle B; Kalinke U; Kirberg J; Hanschmann KM; Waibler Z
    PLoS One; 2016; 11(3):e0149093. PubMed ID: 26959227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a flow cytometry-based potency assay for prediction of cytokine storms induced by biosimilar monoclonal antibodies.
    Madsen NH; Gad M; Larsen J
    J Immunol Methods; 2022 Mar; 502():113231. PubMed ID: 35122772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies.
    Bailey L; Moreno L; Manigold T; Krasniqi S; Kropshofer H; Hinton H; Singer T; Suter L; Hansel TT; Mitchell JA
    J Pharmacol Toxicol Methods; 2013; 68(2):231-239. PubMed ID: 23280407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture.
    Findlay L; Sharp G; Fox B; Ball C; Robinson CJ; Bird C; Stebbings R; Eastwood D; Wadhwa M; Poole S; Thorpe R; Thorpe SJ
    Cytokine; 2011 Jul; 55(1):141-51. PubMed ID: 21493088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.
    Wolf B; Morgan H; Krieg J; Gani Z; Milicov A; Warncke M; Brennan F; Jones S; Sims J; Kiessling A
    Cytokine; 2012 Dec; 60(3):828-37. PubMed ID: 22986013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The blood endothelial cell chamber - An innovative system to study immune responses in drug development.
    Stančič B; Qvarfordt B; Berglund MM; Brenden N; Sydow Bäckman M; Fransson M; Nordling S; Magnusson PU
    Int Immunopharmacol; 2021 Jan; 90():107237. PubMed ID: 33310662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.
    Vessillier S; Fort M; O'Donnell L; Hinton H; Nadwodny K; Piccotti J; Rigsby P; Staflin K; Stebbings R; Mekala D; Willingham A; Wolf B;
    Cytokine X; 2020 Dec; 2(4):100042. PubMed ID: 33458650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies.
    Dhir V; Fort M; Mahmood A; Higbee R; Warren W; Narayanan P; Wittman V
    J Immunotoxicol; 2012; 9(1):34-42. PubMed ID: 22074378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different players generate positive responses in two in vitro cytokine assay formats with aqueous and immobilized TGN1412 analog.
    Iwata Y; Harada A; Kubo C; Inoue T; Tabo M; Mishima M
    Biochem Biophys Res Commun; 2018 Jul; 502(1):91-97. PubMed ID: 29787754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [T lymphocyte activation induced by monoclonal anti-CD3 antibodies: physiopathology of cytokine release].
    Chatenoud L; Bach JF
    C R Seances Soc Biol Fil; 1991; 185(5):268-77. PubMed ID: 1806186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An autologous endothelial cell:peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics.
    Reed DM; Paschalaki KE; Starke RD; Mohamed NA; Sharp G; Fox B; Eastwood D; Bristow A; Ball C; Vessillier S; Hansel TT; Thorpe SJ; Randi AM; Stebbings R; Mitchell JA
    FASEB J; 2015 Jun; 29(6):2595-602. PubMed ID: 25746794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.
    Findlay L; Eastwood D; Stebbings R; Sharp G; Mistry Y; Ball C; Hood J; Thorpe R; Poole S
    J Immunol Methods; 2010 Jan; 352(1-2):1-12. PubMed ID: 19895813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm.
    Panoskaltsis N; McCarthy NE; Stagg AJ; Mummery CJ; Husni M; Arebi N; Greenstein D; Price CL; Al-Hassi HO; Koutinas M; Mantalaris A; Knight SC
    Cancer Immunol Immunother; 2021 Apr; 70(4):1127-1142. PubMed ID: 33033851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics.
    Fletcher EAK; Eltahir M; Lindqvist F; Rieth J; Törnqvist G; Leja-Jarblad J; Mangsbo SM
    Int Immunopharmacol; 2018 Jan; 54():1-11. PubMed ID: 29100032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The calm after the cytokine storm: lessons from the TGN1412 trial.
    St Clair EW
    J Clin Invest; 2008 Apr; 118(4):1344-7. PubMed ID: 18357347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.